RxDoctor Payments Data

David Hochberg, MD

Urology · Tampa, FLNPI 1396709705

Payments from drug & device makers

$4,133in general payments, 2019–2025

Across 156 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$416
  • Astellas Pharma US Inc$409
  • AbbVie$335
  • Ferring Pharmaceuticals Inc.$305
  • Axonics, Inc.$211
  • Blue Earth Diagnostics$183
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,133 in reported general payments places this provider in the 50th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$241,451
Medicare patients
809
Services billed
5,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron146$113,623
GemtesaVibegron41$47,886
EligardLeuprolide Acetate12$16,229
Finasteride602$8,062
Tamsulosin Hcl692$7,374
Silodosin32$4,239
Methenamine Hippurate31$3,138
Oxybutynin Chloride ErOxybutynin Chloride90$2,124
Estradiol38$1,777
Potassium Citrate ErPotassium Citrate20$1,705
Tadalafil19$1,617
Trimethoprim21$1,407
Dutasteride30$1,155
Solifenacin Succinate30$1,041
Tolterodine Tartrate14$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$409$113,623146 claims
Sumitomo Pharma America, Inc.Gemtesa$66$47,88641 claims
Tolmar Pharmaceuticals, Inc.Eligard$73$16,22912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 urology providers in Florida.

Other urology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →